Filament Health Corp. announced that it has entered into a licensing agreement with Reset Pharmaceuticals Inc. Under the terms of the agreement, Filament will license its proprietary botanical psilocybin drug candidate, PEX010, and associated intellectual property, to Reset Pharma for a phase 2 clinical trial for the treatment of demoralization syndrome. PEX010 is formulated as a capsule for oral administration, and is currently being administered in multiple US Food and Drug Administration- and Health Canada-approved phase 1 and phase 2 human clinical trials.

The licensing agreement with Filament grants Reset Pharma use of PEX010 for a phase 2 FDA clinical trial. The licensing agreement with Filament grants Reset Pharma use of PEX010 for a phase 2 FDA clinical trial. Reset Pharma joins a growing list of Filament licensing partners using PEX010 to advance their clinical trial programs. Filament's partners are focused on indications including opioid tapering, palliative care, and alcohol use disorder.